A recent study of orphan drugs approved by the US Food and Drug Administration (FDA) finds that orphan products are more innovative than their non-orphan counterparts, representing roughly 40% of ...

Orphan drug designation has been a fruitful pathway for drug development, but unmet need remains. Whether changes are needed to the legislation, and how orphan drug research can incorporate ...

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$179.5 ...

The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...

Small molecules make up almost half of the 20 most valuable orphan drugs in development across biopharma, according to an Evaluate analysis. A total of 45% of the top 20 orphan drugs in biopharma ...

This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges. In this episode, Kristi Martin, a longtime Washington, DC–based policy ...

The 20th and 21st centuries have witnessed a profound revolution in medical science, significantly enhancing living standards and extending the life expectancy of billions worldwide. However, certain ...

IFx-2.0 received orphan drug designation for cutaneous melanoma, offering benefits like market exclusivity and tax credits. Phase 1 study data showed IFx-2.0 benefits patients resistant to anti-PD1 ...

Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...